Merger aims to advance RNA editing programs.
Korro Bio, a ribonucleic (RNA) editing organization, and Frequency Therapeutics Inc., have announced plans to merge into one company as part of an all-stock transaction. According to Korro Bio, the new organization will concentrate on the enhancement of its portfolio of RNA editing programs.
Current stockholders for Frequency Therapeutics are expected to own approximately 8% of the combined company and pre-merger Korro Bio stockholders are expected to own approximately 92% of the combined company.
“Following comprehensive review and consideration of our strategic options, management and our Board of Directors believe the merger with Korro Bio provides the best opportunity for the company and its stockholders,” said David. L. Lucchino, CEO, Frequency Therapeutics, in a company press release. “Korro Bio’s RNA editing technology leverages genetics transiently, expanding the target space to intervene in biology in a unique manner. We are confident in their ability to bring forward important genetic medicines with the potential to transform the lives of patients.”
Reference: Korro Bio and Frequency Therapeutics Announce Merger Agreement. Business Wire. July 14, 2023. Accessed July 14, 2023. https://www.businesswire.com/news/home/20230714609713/en/Korro-Bio-and-Frequency-Therapeutics-Announce-Merger-Agreement
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.